SuperworthShuttle Pharmaceuticals EPS SHPH
Diluted earnings per share by quarter and over the last twelve months, from 2022.
- Last 12 months, to Jun 30, 2026
- −$27.40
- Latest quarter, Q2 FY26
- −$3.10
- Fiscal year 2025
- −$128.91
Shuttle Pharmaceuticals' earnings per share was −$27.40 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$3.10.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$128.91 | n/a |
| FY2024 | −$928.40 | n/a |
| FY2023 | −$882.50 | n/a |
| FY2022 | −$600.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$3.10 | n/a | −$27.40 | |
| Q1 FY26 | −$4.30 | n/a | −$57.21 | |
| Q4 FY25 | −$9.50 | n/a | −$128.91 | |
| Q3 FY25 | −$10.50 | n/a | −$200.81 | |
| Q2 FY25 | −$32.91 | n/a | −$588.61 | |
| Q1 FY25 | −$76.00 | n/a | −$796.90 | |
| Q4 FY24 | −$81.40 | n/a | −$928.40 | |
| Q3 FY24 | −$398.30 | n/a | −$1052.00 | |
| Q2 FY24 | −$241.20 | n/a | −$881.20 | |
| Q1 FY24 | −$207.50 | n/a | −$947.50 | |
| Q4 FY23 | −$205.00 | n/a | −$882.50 | |
| Q3 FY23 | −$227.50 | n/a | −$797.50 |
Against its peers
Companies in Drug Manufacturers - General nearest Shuttle Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SHPHShuttle Pharmaceuticals | −$27.40 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Shuttle Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.